This week some of us with decanting to Edinburgh for the annual Association of Neurologists meeting.
From an MS perspective, we will have lots to discuss including whether or not the UK MS community has the appetite to take on one, or all of these, studies. Which one do you think is the most important?
The SALVAGE study, which is challenging NHS England’s DMT stopping criteria and saying that even if you end up in a wheelchair it is worth protecting your upper limb function.
The ADIOS study. This is questioning whether or not we need to dose ocrelizumab continuously, or can we use it as an immune reconstitution therapy (IRT), or using adaptive dosing based on peripheral memory B-cell kinetics.
The #AttackMS study to treat MS as early as possible to see if we can maximise disease outcomes for people with CIS or early MS.
Don’t be shy we need you, and the wider MS community, to get behind these studies if we are to have a chance of getting them funded.